Denali therapeutics inc. (DNLI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
Operating activities
Net loss

-197,614

-36,240

-88,185

-86,652

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

8,000

7,400

3,100

1,500

Stock–based compensation expense

38,378

18,791

4,409

2,951

Net amortization of discounts on marketable securities

5,019

2,705

-753

-304

Non-cash operating lease expense

0

3,438

0

0

Non-cash operating lease expense

864

0

0

-

Gain on disposal of property and equipment

-

-

-

-3

Other non-cash items

351

36

-1

-

Fair value of common stock issued in connection with asset acquisition

-

-

-

5,280

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-6,675

18,290

-73

533

Accounts payable

1,033

-526

207

161

Accruals and other current liabilities

1,500

9,113

3,578

5,357

Contract liabilities

-6,286

68,777

0

0

Operating lease liability

1,253

0

0

-

Other non-current liabilities

0

379

-553

-248

Net cash used in operating activities

-151,576

50,116

-76,635

-71,908

Investing activities
Purchases of marketable securities

369,696

557,930

179,789

226,370

Purchases of property and equipment

17,919

3,393

2,875

6,134

Purchase of other investments

-

-

-

500

Maturities and sales of marketable securities

535,327

273,901

141,498

14,000

Net cash used in investing activities

147,712

-287,422

-41,166

-219,004

Financing activities
Issuance of common stock in connection with the Takeda Collaboration Agreement

0

94,406

0

0

Proceeds from public offering of common stock, net of issuance costs

0

0

265,619

0

Proceeds from issuance of convertible preferred stock, net of issuance costs

0

0

29,971

300,365

Proceeds from exercise of awards under equity incentive plans

6,190

3,999

733

111

Net cash provided by financing activities

6,190

97,019

296,323

300,476

Net increase (decrease) in cash, cash equivalents and restricted cash

2,326

-140,287

178,522

9,564

Supplemental disclosures of cash flow information
Tenant improvements provided by the landlord

11,343

14,561

0

0

Property and equipment purchases accrued but not yet paid

0

335

103

233

Deferred IPO costs incurred but not yet paid

0

0

1,358

0

Convertible preferred stock issuance costs incurred but not yet paid

0

0

44

0

Common Stock
Payments of issuance costs related to issuance of stock

0

1,342

0

0

Preferred Stock
Payments of issuance costs related to issuance of stock

0

44

0

-

Convertible Preferred Stock
Payments of issuance costs related to issuance of stock

-

-

-

0